Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 5-Methoxy-2-Aminoindane
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Clearmind Medicine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Clearmind Announces Long-Term Licensing Agreement with Leading Israeli Research Center Now
Details : Under the agreement, Clearmind will use the joint patent it has with BIRAD for innovative cocaine treatment using CMND-100 (5-methoxy-2-aminoindane), its novel psychedelic molecule.
Brand Name : CMND-100
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 01, 2024
Lead Product(s) : 5-Methoxy-2-Aminoindane
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Clearmind Medicine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?